{"cluster": 62, "subcluster": 1, "abstract_summ": "Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity.The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity.Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations.Here we report the drug target and mechanism of action of potential antiviral drug Arbidol for SARS-CoV-2 infections.The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter.", "title_summ": "Exportin 1 inhibition as antiviral therapyThe challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsSofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemicThe SARS-CoV-2 main protease as drug targetExploiting Existing Molecular Scaffolds for Long-Term COVID TreatmentMolecular Investigation of SARS\u2013CoV-2 Proteins and Their Interactions with Antiviral DrugsSimeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivirBiophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targetsShould we try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?", "title_abstract_phrases": "Should we try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity.Here we report the drug target and mechanism of action of potential antiviral drug Arbidol for SARS-CoV-2 infections.Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity.Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations.Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?"}